It didn't take long for sparks to fly Tuesday when the cadre of Big Pharma executives sat down before the Senate Finance Committee to defend their price-setting decisions. But some CEOs had to scramble more than others.
The current structure of reimbursement for drugs in the U.S. is “regressive” and ultimately hurting patients, pharmaceutical executives said Tuesday at a Senate hearing.
This email was sent to newsletter@newslettercollector.com as part of the FiercePharma email list which is administered by FierceMarkets, 1900 L Street NW, Suite 400, Washington, DC 20036, (202) 628-8778.
